Expertise: Work with Government and Non-profit Healthcare Agencies
For over 15 years, we have worked extensively with governmental and non-profit healthcare agencies on such activities as organizational redesign for higher effectiveness, development of new processes for faster throughput, and training for increased organizational communication. This gives us an in-depth knowledge of the requirements that such novel environments require.
Dilts DM, Rosenblum D, and Trochim WM, (2012) “A Virtual National Laboratory for Re-Engineering Clinical and Translational Science,” Science Translational Medicine, 4(118) 118cm2. PMID:22277966.
Salomon RM, Urbano Blackford J, Rosenbloom ST, Seidel S, Wright Clayton E, Dilts DM, Finder SG (2010) “Openness of Patients’ Reporting with use of Electronic Records: Psychiatric Clinician’s Views,” J Am Med Inform Assoc, 17(1):54-60. PMID: 20064802
Dilts DM, Khamalah J, and Plotkin AD, (1994) “Clinical Low Vision Resource Usage Prediction,” Optometry & Vision Science, 71(7): 422-436. PMID: 7970557
Other Work Related to Work with Government and Non-profit Healthcare Agencies
1. Parker C, Snyder R, Jefford M, Dilts DM, Wolfe R, Millar J (2017) “A Randomized Control Trial of an Additional Funding Intervention to Improve Clinical Trial Enrollment”, J of the National Comprehensive Cancer Network (JNCCN),15(9): 1104-1110. PMID: 28874595
2. Massett, H, Dilts DM, Bailey R, Berktold J, Ledsky R, Atkinson (2017) “Raising Public Awareness of Clinical Trials: Development of Messages for a National Health Communication Campaign,” ˆJ of Health Communications 22(5):373-385. PMID:28339327
3. Dilts DM, Zell A, Orwoll E (2015) “A Novel Approach to Measuring Efficiency of Scientific Research Projects: Data Envelopment Analysis.” Clinical and Translational Science. 8(5):495-501. PMID:26243147
4. Perry D, Sperling R, Katz R, Berry, Dilts DM, Hanna D., … & Bens C. (2015). Building a roadmap for developing combination therapies for Alzheimer’s disease. Expert Review of Neurotherapeutics, 15(3), 327-333. PMID: 25708309
5. Dilts DM, (2013) “A 3+1 Level Evaluation Model for CRM”, Evaluation & the Health Professions 36(4):464-477 PMID: 23908383.
6. Grazier KL, Trochim W, Dilts DM, Kirk R (2013) “Estimating Return on Investment in Translational Research: Methods and Protocols”, Evaluation & the Health Professions, 36(4):478-491. PMID: 23925706
7. Denicoff AM (plus 28 others), (2013) “The NCI-ASCO Cancer Trial Accrual Symposium: Summary and Recommendations,” J of Oncology Practice 9(6): 267-76. PMID:24130252
8. Hirsh BR, Califf RM, Cheng SK, Tasneem A, Horton J, Chriswell K, Schulman KA, Dilts DM, and Abernethy AP (2013) “Design of Oncology Clinical Trials: Insights from a Systematic Analysis of ClinicalTrials.gov,” JAMA Internal Medicine, 173(11):972-979. PMID:23699837.
9. Dilts DM, Rosenblum D, and Trochim WM, (2012) “A Virtual National Laboratory for Re-Engineering Clinical and Translational Science,” Science Translational Medicine, 4(118) 118cm2. PMID:22277966.
10. Massett H, Parreco LK, Padberg RM, Richmond ES, Rienzo, ME, Ryan Leonard CE, Quesenbery W, Killam HW, Johnson, and Dilts DM (2011) “AccrualNet: Addressing low accrual via a knowledge-based, community of practice Platform,” J of Oncology Practice, 7(6): e32-e39. PMID:22379429.
11. Kitterman, D, Cheng, S, Dilts DM, and Orwoll, ES, (2011) “The Prevalence and Economic Impact of Low Enrolling Clinical Studies at an Academic Medical Center,” Academic Medicine 86(11): 1360-66. PMID:21952064
12. Cheng S, Dietrich M, Dilts DM (2011) “Predicting Accrual Achievement: Monitoring Accrual Milestones of NCI-CTEP Sponsored Clinical Trials,” Clin Cancer Res. 17: 1947-55. PMID:21447723
13. Dilts DM, Cheng S, Crites JS, Sander AB, Doroshow J, (2010) “Phase III Clinical Trial Development: A Process of Chutes & Ladders,” Clin Cancer Res. 16(22): 5381-89. PMID:21062928
14. Cheng S, Dietrich M, Dilts DM (2010) “A Sense of Urgency: Evaluating the Link Between Clinical Trial Development Time and the Accrual Performance of CTEP-Sponsored Studies,” Clin Cancer Res, 16(22): 5557-63. PMID:21062929
15. Salomon RM, Urbano Blackford J, Rosenbloom ST, Seidel S, Wright Clayton E, Dilts DM, Finder SG (2010) “Openness of Patients’ Reporting with use of Electronic Records: Psychiatric Clinician’s Views,” J Am Med Inform Assoc, 17(1):54-60. PMID: 20064802
16. Dilts DM, Sander AB, Cheng S, Crites J, Ferranti L, Wu, A, Finnigan S., Friedman S, Mooney M, Abrams J, (2009) “The Steps and Time to Process Phase III Clinical Trials at the Cancer Therapy Evaluation Program,” J of Clin Oncol, 27(11): 1761-6. PMID: 19255315
17. Dilts DM, Ridner, SH, Franco A, Murphy B, (2009) “Patients with Cancer and E-mail: Implications for Clinical Communication,” J of Supportive Care in Cancer, 17(8): 1049-1056. PMID:19050941.
18. Dilts DM, Sandler AB, Cheng S, Crites J, Ferranti L, Wu A, Gray R, MacDonald J, Marinucci D, Comis R. (2008) “Development of Clinical Trials in a Cooperative Group Setting: The Eastern Cooperative Group,” Clin Cancer Res, 14(11):3427-33. PMID: 18519773
19. Dilts DM and Sandler AB, (2006) “The “Invisible” Barriers to Clinical Trials: The impact of Structural, Infrastructural, and Procedural Barriers to Opening Oncology Clinical Trials,” J Clin Oncol, 24(28): 4545-52. PMID: 17008693
20. Dilts DM, Sandler AB, Baker M, Cheng S, George SL, Karas KS, McGuire S, Menon G, Reusch J, Sawyer D, Scoggins M, Wu A, Zhou K, Schilsky RL (2006) “Processes to Activate Phase III Clinical Trials in a Cooperative Oncology Group: The Case of the Cancer Leukemia Group B (CALGB), J Clin Oncol, 24(28): 4553-57. PMID: 17008694
21. Khamalah J and Dilts DM (2001) “Determining Resource Needs for Specialty Ambulatory Clinics using Classification/Assignment Methods,” Int J of Operations and Quantitative Management, 7(4): 241-256.
22. Dilts DM, Khamalah J, and Plotkin AD, (1994) “Clinical Low Vision Resource Usage Prediction,” Optometry & Vision Science, 71(7): 422-436. PMID: 7970557
23. Miles, Paul, Bingham, J, and Dilts DM (2002) “Research as a quality improvement activity,” Letter to Editor JAMA, Feb 20; 287(7): 843-4. PMID: 11851572
24. Dilts DM (2014) “Time has come to raise the bar in oncology clinical trials,” J Clin Onc, 30, PMID:22454422 doi: 10.1200/JCO.2013.53.8009
25. Ferranti, L, Cheng S, and Dilts DM (2010) “On Baseball, Medical Decision Making and Innumeracy,” Chapter 18 in Decision Making Wiley, (editors: P Nutt and D Wilson).
26. Pathak SD and Dilts DM (2006) “Investigating evolution in the US healthcare industry,” Decision Sciences Institute (DSI) National Meeting, (November)
27. Belser, Duncan, Aronsky, Dominik, Dilts DM and Ferreira J (2004) “Developing an Emergency Department Information System: A Case History,” in Transforming Health Care Through Information: Case Studies, Second Edition, editors: NM Lorenzi, J Ash, J. Einbinder, W. McPhee, and L. Einbinder, New York: Springer-Verlag.
28. Belser, Duncan and Dilts DM (2004) “A Research-Based Approach to Investment Decisions in Healthcare Information Technology: The VCBH ROI Model,” DSI National Meeting (November).
29. Dilts DM and Chuang, R. (1998) “Health Care at a Distance: Impact on Service Quality Perceptions,” Proceedings of the DSI National Meeting,.
30. Khamalah, J. and Dilts DM (1997) “Predicting Patient Resource Needs: A Methodology for Ambulatory Care,” Proceedings of DSI National Meeting,, pp. 1464-1466.
31. Khamalah, J, and Dilts DM, (1994) “Service Industry Robotics: Examples in Health Care,” Proceedings of the DSI National Meeting,, pp. 1904-1906.
32. Dilts D, Cheng S, Cronin K, Fearn P, Feuer E, Friedman S, Kosary C, Lam C, Mariotto A, Negoita S, Petkov V, Penberthy L (2017) “An Innovative Approach to Developing the SEER-Wide Quality Audit Plan,” North American Association of Central Cancer Registries (NAACCR), June.
33. Parker C, Millar JL, Dilts DM, Jefford M, Wolfe R, Snyder R (2015) “A randomized control trial (RCT) to improve enrolment to cancer clinical trials” J Clin Oncol 33:15s (suppl; abstr: 6514).
34. Dilts DM, Cheng SK, Stover-Fiscalini A., Kennedy Thompson, C. Hogarth, M, Esserman L, (2014) “Barriers to creating the next-generation cancer registry”, J Clin Oncol 32:15s (suppl; abstr e17682).
35. Massett, HA, Jaeckle, KA, Dilts DM, Denicoff, A, Souhan, E, Hopkins JR, Singh Mann, B, (2013) “Rapid online feedback to improve clinical trial accrual: CODEL anaplastic glioma (AG) (NCCTG/Alliance N0577) as a model”, J Clin Oncol 31:15s (suppl; abstr 1596).
36. Lopez-Chavez A, Thomas A, Rajan A, Steinberg SM, Dilts DM, Doyle A, Giaccone G (2013) “CUSTOM (Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies trial): A radical redesign of clinical trial structure–Use of mass customization and product postponement.” J Clin Oncol 30:15s (suppl; abstr 6524).
37. Cheng SK, Hirsch BR, Califf RM, Tasneem A, Schulman KA, Abernethy AP, Dilts DM (2012) “Geographic and network analysis of oncology trials: Portfolio assessment of ClinicalTrial.gov” J Clin Oncol 30:15s (suppl; abstr 6047).
38. Hirsch BR, Mitchell A, Cheng SK, Califf RM, Tasneem A, Dilts DM, Abernethy AP (2012) “Improving the impact of clinical research: A systematic analysis of kidney cancer trials” J Clin Oncol 30:15s (suppl; abstr 6051).
39. Hirsch BR, Califf RM, Cheng SK, Tasneem A, Chiswell K, Horton JR, Schulman KA, Dilts DM, Abernethy AP (2012) “The State of the Oncology Clinical Trials Portfolio: Insights from ClinicalTrial.gov”, Society of Clinical Trials Meeting (May).
40. Dilts DM, Peters, C, Stadum, S, Cheng, SK, “Where you stand depends upon where you sit: Alignment of quality measures to strategic intentions,” ASCO’s Quality Care Symposium, 2012.
41. Kitterman D, Cheng SK, Dilts DM, Orwoll ES (2011) “An etiologic survey of factors that contribute to non-enrolling clinical studies,” NCRR Clinical Research Management Workshop, Bethesda MD (Jun)
42. Kethert KH, Cheng SK, Nauman DJ, Dilts DM, Sandler AB, Chui SY (2011) “Implementation of a prospective screening tool for breast cancer clinical trial eligibility at an NCI designated cancer center,” J Clin Oncol 29:15s (suppl; abstr 6052)
43. Massett H, Parreco LK, Padberg RM, Richmond E, Dilts DM (2011) “AccrualNet: a novel approach to addressing clinical trial accruals through a knowledge-based, community of practice platform,” J Clin Oncol 29 (suppl; abstr e16621)
44. Dilts DM, Cheng SK, Wiltrout RH, Dahut WL, Bronez M, Helman LJ (2011) “Strategic alignment of clinical trials at the National Cancer Institute Center for Cancer Research: Development of the clinical mission and baseline portfolio metrics,” J Clin Oncol 29 (suppl; abstr e16619)
45. Stahl DC, Cheng SK, Lee E, Dilts DM (2011) “Benchmarking of oncology clinical trial metrics across AACI member centers,” J Clin Oncol 29 (suppl; abstr e16613)
46. King A, Earnest J, Lembach J, Lycette J, Kelleher C, Dilts DM (2010) “Axis Definitions for CTSA Portfolio Analysis ,” National Center for Research Resources (NCRR), Evaluation Key Function Meeting, Bethesda MD (Dec)
47. King A, Earnest J, Lembach J, Lycette J, Kelleher C, Dilts DM (2010) “Evaluation Key Function Committee December 2010 Meeting,” National Center for Research Resources (NCRR), Evaluation Key Function Meeting, Bethesda MD (Dec)
48. Cheng S, Dietrich, M, Finnigan S, Dilts DM (2010) “Early indicators of accrual success: Time-to-first-patient and accrual performance at an anticipated enrollment milestone-A study of NCI-CTEP-sponsored clinical trials” J Clin Oncol 28:15s (suppl; abstr 6001)
49. Dilts DM, Massett H (2010) Impact of trial development time on accruals at CCOPs: The case of the MARVEL trial”. American Society of Clinical Oncology, Chicago, IL. (Abstract #e16505)
50. Cheng S, Dietrich, M, Finnigan S, Sandler A, Crites J, Ferranti L, Wu A, Dilts DM (2009) “A Sense of Urgency: evaluating the link between clinical trial development time and the accrual performance of CTEP-sponsored studies,” J Clin Oncol 27:15s (suppl; abstr 6509)
51. Dilts DM, Sandler AB, Cheng S, Crites J, Ferranti L, Wu A, Bookman M, Thomas J, and Ostroff J, (2008) “Accrual to Clinical Trials at Selected Comprehensive Cancer Centers,” 26(15S): 6543
52. Dilts DM, Sandler AB, Cheng S, Crites J, Ferranti L, and Wu A (2008), “Setups in Oncology Clinical Trials: a missing opportunity for improvement,” EurOMA 2008.
53. Dilts DM, Sandler AB, Cheng S, Crites J, Ferranti L, and Wu A (2008), “Are Cancer Clinical Trials in the USA Going the Way of Oldsmobile?,” Production and Operations Management Society 2008.
54. Dilts DM (2006) “Applications of OM Techniques in Improving Drug Clinical Trials,” Production and Operations Management Society International Conference, Shanghai, China, June.
55. Dilts DM (2006) “Applications of OM techniques in Improving the Delivery of Healthcare” (Panel presentation) Production and Operations Management Society, Boston, April.
56. Ferranti, L and Dilts DM (2005) “A Review of Medical Registries and Outcomes: Potential Use for Real-Time Improvement in Patient Safety: The Dearth of Real-Time Science-Based Medicine,” Academy Health Annual Research and Health Policy Conference, Boston (Poster Presentation).
57. Xie, Bin and Dilts DM (2005) “Effects of Patient Obtained Medical Information (POMI) on Healthcare Services Utilization in U.S. Counties,” Academy Health Annual Research and Health Policy Conference, Boston (Poster Presentation).
58. Piasecki JK, Calhoun E, Engelberg J, Rice W, Dilts DM, Belser D, Aronsky D, Jones I, Mason D, Stead B, (2005) “Computerized provider order entry in the emergency department: pilot evaluation of a return on investment analysis instrument,” AMIA Symposium Proceedings, p. 1081. PMID: 16779368
59. Dilts DM, Elaine Chen Wang, and Barbara Murphy (2005) “Patient Obtained Medical Information used by cancer patients and their companions,” J Clin Oncol 23:16s (suppl; abstr 6056).
60. Flores, Ann Marie, Dilts DM, and Murphy, Barbara (2004) “Disparities and Unmet Needs for E-Mail Use in Cancer Patients,” J Clin Oncol 22:16s (suppl; abstr 8254).
61. Ferranti, Lori and Dilts DM (2003) “A Systematic Review of Types and Uses of Medical Registries,” 20th Annual Research Meeting of the Academy of Health. (poster) (June)
62. Dilts DM and Chuang, R. JW. (1997) “Perceptions of Service Quality in Telemedicine” Academy of Management Annual Meeting.
63. Khamalah, J, and Dilts DM, (1997) “The Application of ‘Traditional’ Manufacturing Management Techniques in Health Care Resource Usage Prediction,” Operation Management Association Forum, April.
64. (2015) “Observations on Clinical Research: Some Ideas for NHLBAC”, National Heart, Lung Blood Advisory Council, NIH,(June).
65. (2015) “Going Beyond the Norm: Some Ideas for the British Columbia Cancer Agency” British Columbia Cancer Agency Retreat, Vancouver, BC(May)
66. (2015) “Value-based Structures: Centralization and Decentralization”, NIH-Association of Biomolecular Resource Facilities Workshop on Enhancing Efficiency of Research Core Facilities, St Louis, MO(Mar)
67. (2014) “The Future of Clinical Research”, Clinical Trials Advisory Committee, Commonwealth of Australia, Sydney, AUS(Nov)
68. (2014) “Understanding the linkages among mission, processes and metrics in running a core”, Keynote address, Midwest & Southeast Association of Biomolecular Resource Facilities 2014 Annual Meeting, Nashville TN(Oct).
69. (2014) “The Promise and Perils in Clinical Trials,” Monash University, Melbourne, Australia(August, presented twice)
70. (2014) “Observations on Cancer Research from a Non-Medical Researcher,” keynote speech, Cancer Institute of New South Wales Annual Awards Banquet(August)
71. (2014) “The Importance of Doing Trials Right While doing the Right Trials,” Ministry of Health, NSW, Australia(August)
72. (2014) “Overcoming the Barriers of Transparency in Clinical Trial Data Access,” ASCO National Meeting, Chicago IL(June)
73. (2014) “Integration Metrics: Linking Mission, Science, Resources and Education,” NICHD Division of Intramural Research, Scientific Retreat, Bethesda, MD(Feb).
74. (2013) “Prioritizing and Measuring Clinical Research,” NIH Clinical Research Subcommittee, Bethesda, MD(Sept).
75. (2013) “Cooperative Groups, Version 3.0”, Palliative Care Research Consortium meeting, Chicago, IL(Sept).
76. (2013) “Consortium or not to Consortium”, ACT-AD National Meeting on Alzheimer’s Research, Washington, DC(May)
77. (2013) “A Model for Evaluating the Efficiency and Effectiveness of Clinical Research,” Medical Executive Committee, NIH, Bethesda MD(May).
78. (2013) “Process Improvement: Linking Improvement to Strategy,” Oregon Health Financial Manager’s Association, Portland, OR(Feb)
79. (2012) “Metrics for Clinical Trials: Lessons Learned”, CTSA Annual Evaluation Meeting, Bethesda MD(Oct)
80. (2011) “Management Principles in Healthcare” Southern Health, Melbourne AUS(Nov) and The Albert Hospital System, Melbourne AUS(Nov)
81. (2011) “Process Mapping – Purpose, Method & Expected Results,” University of Cincinnati Academic Health Center, Center for Clinical & Translational Science & Training(Sept)
82. (2011) “Precompetitive Collaboration: Lessons from History and Other Industries,” UCSF Accelerating Targeted Cancer Drug-Biomarker Development Conference, San Francisco CA(May)
83. (2011) “Clinical Research as a Complex Adaptive System,” Arizona State University Institute for Complexity, Phoenix, AZ(Mar)
84. (2011) “Mis-Measurement of Quality in IRBs: Thoughts from Other Industries,” 13th annual Subject Protection conference, Schulman Group, Cincinnati Children’s and the University of Kentucky, Cincinnati, OH(Sept).
85. (2010) “Clinical Trial and Regulatory Process Mapping, the Clinical Trials and Regulatory Pathways Working Group at the Center for Global Development,(Oct)
86. (2010) “Beyond Efficiency: A Strategic Approach to Clinical Research,” Keynote address, 10th Annual Oncore Users Group Madison, WI(Aug)
87. (2010) “The Science of Trial Selection, Infrastructure, and Operations,” NCI-ASCO Symposium on Accruals, Chicago IL(Apr)
88. (2009) “The Need for Operations Management in Healthcare: The Case of Oncology Clinical Trials,” Distinguished Lecture, Supply Chain Management Area, Sir Wilfrid Laurier University(Dec)
89. (2009) “Envisioning the Future: Roadmaps & Roadmapping” keynote address to Radiological Society of North America QIBA Roadmapping committee, Chicago IL(Mar)
90. (2009) “Envisioning the future: Lessons from the past(& present) in Oncology Clinical Trials”, keynote speech to Johns Hopkins Sidney Kimmel Comprehensive Cancer Center strategic retreat, Baltimore MD(Mar)
91. (2008) “Building Networks: Observations from Oncology and Non-Medical Industries”, keynote address for the NHLBI Workshop on Sickle Cell Disease. Washington, DC(Oct)
92. (2008) “Impact of Pathways in the Business and Technological World,” keynote address for the NCI Translates, NCI Translational Science Meeting, Washington, DC(Nov).
93. Behringer B, Omohundro E, Boswell D, Evans D and Ferranti L. The Tennessee Department of Health WORKshops on the Use of Secondary Data for Community Health Assessment, 2012. Preventing Chronic Disease. (2014). 11:130206. DOI: http://dx.doi.org/10.5888/pdc.11.130260.
94. Ferranti L. TPHA East and Middle Grand Region Meeting, “Using LEAN in HealthCare Interactive Setting”. (2013)
95. Ferranti L. TPHA West Grand Region Meeting LEAN Principles (2013)
96. L Ferranti, PhD., Principal Investigator and V. Pinkney. Tennessee Disparity and Diversity in Public Health, “Using Data from the 2012-2013 Community Health”. CDC Poster presentation National Meeting -Assessment to Make a Difference. (April 2013).
97. Ferranti L. Vanderbilt University, School of Global Health, “The Use of Medical Registries?”. (2012)
98. Ferranti, L; “A Systematic Review: Pediatric Asthma Compliance and Outcomes.” Vanderbilt University School of Nursing Research Day, August 2002. (2nd place award)
99. Rosow CE, DiBiase PM, Zaslavsky A, Burch L. “Propofol vs. thiopental in in-patients: Comparison of recovery after general anesthesia” Proceedings of the Annual Meeting of the American Society of Anesthesiologists, Anesthesiology 1993; 79 (3): A-336.
100. Rosow CE, Burch L. “Bispectral Analysis for Monitoring Hypnotic Drug Effects” (submitted) 1999.
101. Ferranti, L. “What is a Medical Registry?” Unpublished paper presented at Owen Graduate School of Management, Vanderbilt University, Nashville, TN, March, 2002
102. Ferranti, L. “Pediatric Asthma Compliance and Outcomes”. Paper presented at Vanderbilt University School of Nursing, Annual Research Day Nashville, TN, August, 2001.
103. Ferranti, L. “School Based Health Clinics: Their Advantages and the Challenges They Face.” Unpublished paper presented at Owen Graduate School of Management, Vanderbilt University, Nashville, TN, April,2001.
104. Ferranti, L. Internet Pharmaceutical Sales. Unpublished paper presented at Owen Graduate School of Management,
105. Coyne, T. & Ferranti, L. Health Insurance Portability and Accountability Act. Unpublished paper presented at Vanderbilt University School of Nursing, Nashville, December, 2000.
2. Massett, H, Dilts DM, Bailey R, Berktold J, Ledsky R, Atkinson (2017) “Raising Public Awareness of Clinical Trials: Development of Messages for a National Health Communication Campaign,” ˆJ of Health Communications 22(5):373-385. PMID:28339327
3. Dilts DM, Zell A, Orwoll E (2015) “A Novel Approach to Measuring Efficiency of Scientific Research Projects: Data Envelopment Analysis.” Clinical and Translational Science. 8(5):495-501. PMID:26243147
4. Perry D, Sperling R, Katz R, Berry, Dilts DM, Hanna D., … & Bens C. (2015). Building a roadmap for developing combination therapies for Alzheimer’s disease. Expert Review of Neurotherapeutics, 15(3), 327-333. PMID: 25708309
5. Dilts DM, (2013) “A 3+1 Level Evaluation Model for CRM”, Evaluation & the Health Professions 36(4):464-477 PMID: 23908383.
6. Grazier KL, Trochim W, Dilts DM, Kirk R (2013) “Estimating Return on Investment in Translational Research: Methods and Protocols”, Evaluation & the Health Professions, 36(4):478-491. PMID: 23925706
7. Denicoff AM (plus 28 others), (2013) “The NCI-ASCO Cancer Trial Accrual Symposium: Summary and Recommendations,” J of Oncology Practice 9(6): 267-76. PMID:24130252
8. Hirsh BR, Califf RM, Cheng SK, Tasneem A, Horton J, Chriswell K, Schulman KA, Dilts DM, and Abernethy AP (2013) “Design of Oncology Clinical Trials: Insights from a Systematic Analysis of ClinicalTrials.gov,” JAMA Internal Medicine, 173(11):972-979. PMID:23699837.
9. Dilts DM, Rosenblum D, and Trochim WM, (2012) “A Virtual National Laboratory for Re-Engineering Clinical and Translational Science,” Science Translational Medicine, 4(118) 118cm2. PMID:22277966.
10. Massett H, Parreco LK, Padberg RM, Richmond ES, Rienzo, ME, Ryan Leonard CE, Quesenbery W, Killam HW, Johnson, and Dilts DM (2011) “AccrualNet: Addressing low accrual via a knowledge-based, community of practice Platform,” J of Oncology Practice, 7(6): e32-e39. PMID:22379429.
11. Kitterman, D, Cheng, S, Dilts DM, and Orwoll, ES, (2011) “The Prevalence and Economic Impact of Low Enrolling Clinical Studies at an Academic Medical Center,” Academic Medicine 86(11): 1360-66. PMID:21952064
12. Cheng S, Dietrich M, Dilts DM (2011) “Predicting Accrual Achievement: Monitoring Accrual Milestones of NCI-CTEP Sponsored Clinical Trials,” Clin Cancer Res. 17: 1947-55. PMID:21447723
13. Dilts DM, Cheng S, Crites JS, Sander AB, Doroshow J, (2010) “Phase III Clinical Trial Development: A Process of Chutes & Ladders,” Clin Cancer Res. 16(22): 5381-89. PMID:21062928
14. Cheng S, Dietrich M, Dilts DM (2010) “A Sense of Urgency: Evaluating the Link Between Clinical Trial Development Time and the Accrual Performance of CTEP-Sponsored Studies,” Clin Cancer Res, 16(22): 5557-63. PMID:21062929
15. Salomon RM, Urbano Blackford J, Rosenbloom ST, Seidel S, Wright Clayton E, Dilts DM, Finder SG (2010) “Openness of Patients’ Reporting with use of Electronic Records: Psychiatric Clinician’s Views,” J Am Med Inform Assoc, 17(1):54-60. PMID: 20064802
16. Dilts DM, Sander AB, Cheng S, Crites J, Ferranti L, Wu, A, Finnigan S., Friedman S, Mooney M, Abrams J, (2009) “The Steps and Time to Process Phase III Clinical Trials at the Cancer Therapy Evaluation Program,” J of Clin Oncol, 27(11): 1761-6. PMID: 19255315
17. Dilts DM, Ridner, SH, Franco A, Murphy B, (2009) “Patients with Cancer and E-mail: Implications for Clinical Communication,” J of Supportive Care in Cancer, 17(8): 1049-1056. PMID:19050941.
18. Dilts DM, Sandler AB, Cheng S, Crites J, Ferranti L, Wu A, Gray R, MacDonald J, Marinucci D, Comis R. (2008) “Development of Clinical Trials in a Cooperative Group Setting: The Eastern Cooperative Group,” Clin Cancer Res, 14(11):3427-33. PMID: 18519773
19. Dilts DM and Sandler AB, (2006) “The “Invisible” Barriers to Clinical Trials: The impact of Structural, Infrastructural, and Procedural Barriers to Opening Oncology Clinical Trials,” J Clin Oncol, 24(28): 4545-52. PMID: 17008693
20. Dilts DM, Sandler AB, Baker M, Cheng S, George SL, Karas KS, McGuire S, Menon G, Reusch J, Sawyer D, Scoggins M, Wu A, Zhou K, Schilsky RL (2006) “Processes to Activate Phase III Clinical Trials in a Cooperative Oncology Group: The Case of the Cancer Leukemia Group B (CALGB), J Clin Oncol, 24(28): 4553-57. PMID: 17008694
21. Khamalah J and Dilts DM (2001) “Determining Resource Needs for Specialty Ambulatory Clinics using Classification/Assignment Methods,” Int J of Operations and Quantitative Management, 7(4): 241-256.
22. Dilts DM, Khamalah J, and Plotkin AD, (1994) “Clinical Low Vision Resource Usage Prediction,” Optometry & Vision Science, 71(7): 422-436. PMID: 7970557
23. Miles, Paul, Bingham, J, and Dilts DM (2002) “Research as a quality improvement activity,” Letter to Editor JAMA, Feb 20; 287(7): 843-4. PMID: 11851572
24. Dilts DM (2014) “Time has come to raise the bar in oncology clinical trials,” J Clin Onc, 30, PMID:22454422 doi: 10.1200/JCO.2013.53.8009
25. Ferranti, L, Cheng S, and Dilts DM (2010) “On Baseball, Medical Decision Making and Innumeracy,” Chapter 18 in Decision Making Wiley, (editors: P Nutt and D Wilson).
26. Pathak SD and Dilts DM (2006) “Investigating evolution in the US healthcare industry,” Decision Sciences Institute (DSI) National Meeting, (November)
27. Belser, Duncan, Aronsky, Dominik, Dilts DM and Ferreira J (2004) “Developing an Emergency Department Information System: A Case History,” in Transforming Health Care Through Information: Case Studies, Second Edition, editors: NM Lorenzi, J Ash, J. Einbinder, W. McPhee, and L. Einbinder, New York: Springer-Verlag.
28. Belser, Duncan and Dilts DM (2004) “A Research-Based Approach to Investment Decisions in Healthcare Information Technology: The VCBH ROI Model,” DSI National Meeting (November).
29. Dilts DM and Chuang, R. (1998) “Health Care at a Distance: Impact on Service Quality Perceptions,” Proceedings of the DSI National Meeting,.
30. Khamalah, J. and Dilts DM (1997) “Predicting Patient Resource Needs: A Methodology for Ambulatory Care,” Proceedings of DSI National Meeting,, pp. 1464-1466.
31. Khamalah, J, and Dilts DM, (1994) “Service Industry Robotics: Examples in Health Care,” Proceedings of the DSI National Meeting,, pp. 1904-1906.
32. Dilts D, Cheng S, Cronin K, Fearn P, Feuer E, Friedman S, Kosary C, Lam C, Mariotto A, Negoita S, Petkov V, Penberthy L (2017) “An Innovative Approach to Developing the SEER-Wide Quality Audit Plan,” North American Association of Central Cancer Registries (NAACCR), June.
33. Parker C, Millar JL, Dilts DM, Jefford M, Wolfe R, Snyder R (2015) “A randomized control trial (RCT) to improve enrolment to cancer clinical trials” J Clin Oncol 33:15s (suppl; abstr: 6514).
34. Dilts DM, Cheng SK, Stover-Fiscalini A., Kennedy Thompson, C. Hogarth, M, Esserman L, (2014) “Barriers to creating the next-generation cancer registry”, J Clin Oncol 32:15s (suppl; abstr e17682).
35. Massett, HA, Jaeckle, KA, Dilts DM, Denicoff, A, Souhan, E, Hopkins JR, Singh Mann, B, (2013) “Rapid online feedback to improve clinical trial accrual: CODEL anaplastic glioma (AG) (NCCTG/Alliance N0577) as a model”, J Clin Oncol 31:15s (suppl; abstr 1596).
36. Lopez-Chavez A, Thomas A, Rajan A, Steinberg SM, Dilts DM, Doyle A, Giaccone G (2013) “CUSTOM (Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies trial): A radical redesign of clinical trial structure–Use of mass customization and product postponement.” J Clin Oncol 30:15s (suppl; abstr 6524).
37. Cheng SK, Hirsch BR, Califf RM, Tasneem A, Schulman KA, Abernethy AP, Dilts DM (2012) “Geographic and network analysis of oncology trials: Portfolio assessment of ClinicalTrial.gov” J Clin Oncol 30:15s (suppl; abstr 6047).
38. Hirsch BR, Mitchell A, Cheng SK, Califf RM, Tasneem A, Dilts DM, Abernethy AP (2012) “Improving the impact of clinical research: A systematic analysis of kidney cancer trials” J Clin Oncol 30:15s (suppl; abstr 6051).
39. Hirsch BR, Califf RM, Cheng SK, Tasneem A, Chiswell K, Horton JR, Schulman KA, Dilts DM, Abernethy AP (2012) “The State of the Oncology Clinical Trials Portfolio: Insights from ClinicalTrial.gov”, Society of Clinical Trials Meeting (May).
40. Dilts DM, Peters, C, Stadum, S, Cheng, SK, “Where you stand depends upon where you sit: Alignment of quality measures to strategic intentions,” ASCO’s Quality Care Symposium, 2012.
41. Kitterman D, Cheng SK, Dilts DM, Orwoll ES (2011) “An etiologic survey of factors that contribute to non-enrolling clinical studies,” NCRR Clinical Research Management Workshop, Bethesda MD (Jun)
42. Kethert KH, Cheng SK, Nauman DJ, Dilts DM, Sandler AB, Chui SY (2011) “Implementation of a prospective screening tool for breast cancer clinical trial eligibility at an NCI designated cancer center,” J Clin Oncol 29:15s (suppl; abstr 6052)
43. Massett H, Parreco LK, Padberg RM, Richmond E, Dilts DM (2011) “AccrualNet: a novel approach to addressing clinical trial accruals through a knowledge-based, community of practice platform,” J Clin Oncol 29 (suppl; abstr e16621)
44. Dilts DM, Cheng SK, Wiltrout RH, Dahut WL, Bronez M, Helman LJ (2011) “Strategic alignment of clinical trials at the National Cancer Institute Center for Cancer Research: Development of the clinical mission and baseline portfolio metrics,” J Clin Oncol 29 (suppl; abstr e16619)
45. Stahl DC, Cheng SK, Lee E, Dilts DM (2011) “Benchmarking of oncology clinical trial metrics across AACI member centers,” J Clin Oncol 29 (suppl; abstr e16613)
46. King A, Earnest J, Lembach J, Lycette J, Kelleher C, Dilts DM (2010) “Axis Definitions for CTSA Portfolio Analysis ,” National Center for Research Resources (NCRR), Evaluation Key Function Meeting, Bethesda MD (Dec)
47. King A, Earnest J, Lembach J, Lycette J, Kelleher C, Dilts DM (2010) “Evaluation Key Function Committee December 2010 Meeting,” National Center for Research Resources (NCRR), Evaluation Key Function Meeting, Bethesda MD (Dec)
48. Cheng S, Dietrich, M, Finnigan S, Dilts DM (2010) “Early indicators of accrual success: Time-to-first-patient and accrual performance at an anticipated enrollment milestone-A study of NCI-CTEP-sponsored clinical trials” J Clin Oncol 28:15s (suppl; abstr 6001)
49. Dilts DM, Massett H (2010) Impact of trial development time on accruals at CCOPs: The case of the MARVEL trial”. American Society of Clinical Oncology, Chicago, IL. (Abstract #e16505)
50. Cheng S, Dietrich, M, Finnigan S, Sandler A, Crites J, Ferranti L, Wu A, Dilts DM (2009) “A Sense of Urgency: evaluating the link between clinical trial development time and the accrual performance of CTEP-sponsored studies,” J Clin Oncol 27:15s (suppl; abstr 6509)
51. Dilts DM, Sandler AB, Cheng S, Crites J, Ferranti L, Wu A, Bookman M, Thomas J, and Ostroff J, (2008) “Accrual to Clinical Trials at Selected Comprehensive Cancer Centers,” 26(15S): 6543
52. Dilts DM, Sandler AB, Cheng S, Crites J, Ferranti L, and Wu A (2008), “Setups in Oncology Clinical Trials: a missing opportunity for improvement,” EurOMA 2008.
53. Dilts DM, Sandler AB, Cheng S, Crites J, Ferranti L, and Wu A (2008), “Are Cancer Clinical Trials in the USA Going the Way of Oldsmobile?,” Production and Operations Management Society 2008.
54. Dilts DM (2006) “Applications of OM Techniques in Improving Drug Clinical Trials,” Production and Operations Management Society International Conference, Shanghai, China, June.
55. Dilts DM (2006) “Applications of OM techniques in Improving the Delivery of Healthcare” (Panel presentation) Production and Operations Management Society, Boston, April.
56. Ferranti, L and Dilts DM (2005) “A Review of Medical Registries and Outcomes: Potential Use for Real-Time Improvement in Patient Safety: The Dearth of Real-Time Science-Based Medicine,” Academy Health Annual Research and Health Policy Conference, Boston (Poster Presentation).
57. Xie, Bin and Dilts DM (2005) “Effects of Patient Obtained Medical Information (POMI) on Healthcare Services Utilization in U.S. Counties,” Academy Health Annual Research and Health Policy Conference, Boston (Poster Presentation).
58. Piasecki JK, Calhoun E, Engelberg J, Rice W, Dilts DM, Belser D, Aronsky D, Jones I, Mason D, Stead B, (2005) “Computerized provider order entry in the emergency department: pilot evaluation of a return on investment analysis instrument,” AMIA Symposium Proceedings, p. 1081. PMID: 16779368
59. Dilts DM, Elaine Chen Wang, and Barbara Murphy (2005) “Patient Obtained Medical Information used by cancer patients and their companions,” J Clin Oncol 23:16s (suppl; abstr 6056).
60. Flores, Ann Marie, Dilts DM, and Murphy, Barbara (2004) “Disparities and Unmet Needs for E-Mail Use in Cancer Patients,” J Clin Oncol 22:16s (suppl; abstr 8254).
61. Ferranti, Lori and Dilts DM (2003) “A Systematic Review of Types and Uses of Medical Registries,” 20th Annual Research Meeting of the Academy of Health. (poster) (June)
62. Dilts DM and Chuang, R. JW. (1997) “Perceptions of Service Quality in Telemedicine” Academy of Management Annual Meeting.
63. Khamalah, J, and Dilts DM, (1997) “The Application of ‘Traditional’ Manufacturing Management Techniques in Health Care Resource Usage Prediction,” Operation Management Association Forum, April.
64. (2015) “Observations on Clinical Research: Some Ideas for NHLBAC”, National Heart, Lung Blood Advisory Council, NIH,(June).
65. (2015) “Going Beyond the Norm: Some Ideas for the British Columbia Cancer Agency” British Columbia Cancer Agency Retreat, Vancouver, BC(May)
66. (2015) “Value-based Structures: Centralization and Decentralization”, NIH-Association of Biomolecular Resource Facilities Workshop on Enhancing Efficiency of Research Core Facilities, St Louis, MO(Mar)
67. (2014) “The Future of Clinical Research”, Clinical Trials Advisory Committee, Commonwealth of Australia, Sydney, AUS(Nov)
68. (2014) “Understanding the linkages among mission, processes and metrics in running a core”, Keynote address, Midwest & Southeast Association of Biomolecular Resource Facilities 2014 Annual Meeting, Nashville TN(Oct).
69. (2014) “The Promise and Perils in Clinical Trials,” Monash University, Melbourne, Australia(August, presented twice)
70. (2014) “Observations on Cancer Research from a Non-Medical Researcher,” keynote speech, Cancer Institute of New South Wales Annual Awards Banquet(August)
71. (2014) “The Importance of Doing Trials Right While doing the Right Trials,” Ministry of Health, NSW, Australia(August)
72. (2014) “Overcoming the Barriers of Transparency in Clinical Trial Data Access,” ASCO National Meeting, Chicago IL(June)
73. (2014) “Integration Metrics: Linking Mission, Science, Resources and Education,” NICHD Division of Intramural Research, Scientific Retreat, Bethesda, MD(Feb).
74. (2013) “Prioritizing and Measuring Clinical Research,” NIH Clinical Research Subcommittee, Bethesda, MD(Sept).
75. (2013) “Cooperative Groups, Version 3.0”, Palliative Care Research Consortium meeting, Chicago, IL(Sept).
76. (2013) “Consortium or not to Consortium”, ACT-AD National Meeting on Alzheimer’s Research, Washington, DC(May)
77. (2013) “A Model for Evaluating the Efficiency and Effectiveness of Clinical Research,” Medical Executive Committee, NIH, Bethesda MD(May).
78. (2013) “Process Improvement: Linking Improvement to Strategy,” Oregon Health Financial Manager’s Association, Portland, OR(Feb)
79. (2012) “Metrics for Clinical Trials: Lessons Learned”, CTSA Annual Evaluation Meeting, Bethesda MD(Oct)
80. (2011) “Management Principles in Healthcare” Southern Health, Melbourne AUS(Nov) and The Albert Hospital System, Melbourne AUS(Nov)
81. (2011) “Process Mapping – Purpose, Method & Expected Results,” University of Cincinnati Academic Health Center, Center for Clinical & Translational Science & Training(Sept)
82. (2011) “Precompetitive Collaboration: Lessons from History and Other Industries,” UCSF Accelerating Targeted Cancer Drug-Biomarker Development Conference, San Francisco CA(May)
83. (2011) “Clinical Research as a Complex Adaptive System,” Arizona State University Institute for Complexity, Phoenix, AZ(Mar)
84. (2011) “Mis-Measurement of Quality in IRBs: Thoughts from Other Industries,” 13th annual Subject Protection conference, Schulman Group, Cincinnati Children’s and the University of Kentucky, Cincinnati, OH(Sept).
85. (2010) “Clinical Trial and Regulatory Process Mapping, the Clinical Trials and Regulatory Pathways Working Group at the Center for Global Development,(Oct)
86. (2010) “Beyond Efficiency: A Strategic Approach to Clinical Research,” Keynote address, 10th Annual Oncore Users Group Madison, WI(Aug)
87. (2010) “The Science of Trial Selection, Infrastructure, and Operations,” NCI-ASCO Symposium on Accruals, Chicago IL(Apr)
88. (2009) “The Need for Operations Management in Healthcare: The Case of Oncology Clinical Trials,” Distinguished Lecture, Supply Chain Management Area, Sir Wilfrid Laurier University(Dec)
89. (2009) “Envisioning the Future: Roadmaps & Roadmapping” keynote address to Radiological Society of North America QIBA Roadmapping committee, Chicago IL(Mar)
90. (2009) “Envisioning the future: Lessons from the past(& present) in Oncology Clinical Trials”, keynote speech to Johns Hopkins Sidney Kimmel Comprehensive Cancer Center strategic retreat, Baltimore MD(Mar)
91. (2008) “Building Networks: Observations from Oncology and Non-Medical Industries”, keynote address for the NHLBI Workshop on Sickle Cell Disease. Washington, DC(Oct)
92. (2008) “Impact of Pathways in the Business and Technological World,” keynote address for the NCI Translates, NCI Translational Science Meeting, Washington, DC(Nov).
93. Behringer B, Omohundro E, Boswell D, Evans D and Ferranti L. The Tennessee Department of Health WORKshops on the Use of Secondary Data for Community Health Assessment, 2012. Preventing Chronic Disease. (2014). 11:130206. DOI: http://dx.doi.org/10.5888/pdc.11.130260.
94. Ferranti L. TPHA East and Middle Grand Region Meeting, “Using LEAN in HealthCare Interactive Setting”. (2013)
95. Ferranti L. TPHA West Grand Region Meeting LEAN Principles (2013)
96. L Ferranti, PhD., Principal Investigator and V. Pinkney. Tennessee Disparity and Diversity in Public Health, “Using Data from the 2012-2013 Community Health”. CDC Poster presentation National Meeting -Assessment to Make a Difference. (April 2013).
97. Ferranti L. Vanderbilt University, School of Global Health, “The Use of Medical Registries?”. (2012)
98. Ferranti, L; “A Systematic Review: Pediatric Asthma Compliance and Outcomes.” Vanderbilt University School of Nursing Research Day, August 2002. (2nd place award)
99. Rosow CE, DiBiase PM, Zaslavsky A, Burch L. “Propofol vs. thiopental in in-patients: Comparison of recovery after general anesthesia” Proceedings of the Annual Meeting of the American Society of Anesthesiologists, Anesthesiology 1993; 79 (3): A-336.
100. Rosow CE, Burch L. “Bispectral Analysis for Monitoring Hypnotic Drug Effects” (submitted) 1999.
101. Ferranti, L. “What is a Medical Registry?” Unpublished paper presented at Owen Graduate School of Management, Vanderbilt University, Nashville, TN, March, 2002
102. Ferranti, L. “Pediatric Asthma Compliance and Outcomes”. Paper presented at Vanderbilt University School of Nursing, Annual Research Day Nashville, TN, August, 2001.
103. Ferranti, L. “School Based Health Clinics: Their Advantages and the Challenges They Face.” Unpublished paper presented at Owen Graduate School of Management, Vanderbilt University, Nashville, TN, April,2001.
104. Ferranti, L. Internet Pharmaceutical Sales. Unpublished paper presented at Owen Graduate School of Management,
105. Coyne, T. & Ferranti, L. Health Insurance Portability and Accountability Act. Unpublished paper presented at Vanderbilt University School of Nursing, Nashville, December, 2000.